Halozyme Therapeutics Inc. announced that the company is commencing, through wholly owned subsidiary Atlas Merger Sub Inc., a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma Inc. for $5.60 per share in cash.
Walgreens, Teva face San Francisco trial over opioid epidemicAlabama, AmerisourceBergen, Business, California, Cardinal Health, Drug Distributors, Endo, Epidemics, Johnson & Johnson, Lawsuits, Lawsuits, Los Angeles, McKesson, Opioid Lawsuits, Opioids, Opioids, Pharmacies, Pharmacy, Purdue Pharma, San Francisco, Therapeutics, U.S. Opioid Crisis, Walgreens Boots Alliance, West Virginia
San Francisco squared off on April 25 against Walgreens Boots Alliance and three other companies accused of fueling an opioid crisis in the city, the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.
Tennessee Court of Appeals Orders Recusal of Trial Court Judge and Vacates Default Judgment on Liability Against EndoBusiness, Class Action Lawsuits, Endo, Lawsuits, Litigation, Opioid Litigation, Opioid Litigation, Opioid Overdoses, Opioid Prescriptions, Opioids, Opioids, Opioids, Opioids, Opioids, Overdoses, Overturned Verdicts, Prescriptions, Probes, Specialty Pharma, Substance Abuse, Tennessee, Therapeutics, U.S. Opioid Crisis
Endo International plc announced that the Tennessee Court of Appeals reversed a trial court judge’s order denying a motion for recusal by Endo’s wholly owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. in Clay County et al. v. Purdue Pharma, L.P., et al, pending in the Circuit Court for Cumberland County, Tennessee, and remanded the case for transfer to a different judge.
Halozyme Therapeutics announced that the company is acquiring Antares Pharma for $960 million in cash. The news caused Antares stock to rocket 47 percent in premarket trading on April 13.
BioDelivery Sciences International Inc. entered into a definitive merger agreement for Collegium Pharmaceutical Inc. to purchase all outstanding shares of BDSI at $5.60 per share in an all-cash transaction.
The U.S. Food and Drug Administration approved Azurity Pharmaceuticals Inc.’s Fleqsuvy (baclofen oral suspension), 25 mg per 5 mL (5 mg/mL), Concentrated Formulation for the treatment of spasticity from multiple sclerosis or patients with spinal cord injuries and other spinal cord diseases.
Evoke Pharma Inc., a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA Life Science Service LLC, an independent provider of global commercial services to the life science industry, announced an extension of their agreement. The companies will continue collaborating on the commercialization and distribution of Gimoti (metoclopramide) nasal spray in the United States through the end of 2026.
Endo International agreed to pay up to $65 million to resolve claims by the state of Florida and local governments that the drugmaker helped fuel the U.S. opioid epidemic.
Drugmakers Johnson & Johnson, Endo International, AbbVie’s Allergan unit, and Teva Pharmaceutical headed to court on April 19 in California over claims the companies engaged in deceptive marketing practices that fueled the opioid crisis in America.
Digital-first creative agency Code and Theory has established Code and Theory Health – a new business unit dedicated to servicing brands and organizations within the healthcare industry – and added Scout Health, a 100-person agency focused on rare diseases, orphan drugs and specialty pharmaceuticals.